-
Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient
Thursday, February 3, 2022 - 2:53pm | 378Psychedelics biotech startup Entheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) announced the approval by the local Dutch ethics committee for a Phase 1 clinical trial evaluating the pharmacokinetics, pharmacodynamics and safety profile of the psychedelic compound DMT. DMT is known as the active...